3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NIH
2
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
69
Leukemia, Myeloid, Acute
32
Carcinoma, Renal Cell
27
Neoplasm Metastasis
17
Breast Neoplasms
16
Leukemia
15
Neuroblastoma
14
Kidney Neoplasms
14
Lymphoma, Non-Hodgkin
12
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Myelodysplastic Syndromes
10
Recurrence
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Neoplasms
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma
7
Congenital Abnormalities
7
Colorectal Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Skin Neoplasms
5
Multiple Myeloma
5
Lymphoma, Mantle-Cell
5
Lymphoma, Follicular
5
Head and Neck Neoplasms
5
Fallopian Tube Neoplasms
5
Carcinoma, Hepatocellular
5
Rectal Neoplasms
4
Mesothelioma, Malignant
4
Lung Neoplasms
4
Interventions
Oxaliplatin
112
Fluorouracil
104
Leucovorin
91
Irinotecan
91
Capecitabine
59
Bevacizumab
58
Cetuximab
46
Folfox protocol
28
Colonoscopy
24
Panitumumab
19
Chemotherapy, Adjuvant
19
Blood Specimen Collection
19
Drug Therapy
18
Nivolumab
17
Magnetic Resonance Spectroscopy
17
Radiotherapy
16
Exercise
16
Early Intervention, Educational
16
Surveys and Questionnaires
15
Laparoscopy
15
Surgical Procedures, Operative
13
Floxuridine
13
Biopsy
13
trifluridine tipiracil drug combination
12
pembrolizumab
12
XELOX
12
Neoadjuvant Therapy
11
Methods
11
Immunohistochemistry
11
Celecoxib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Colonic Neoplasms
×
Interleukin-2
×
Clear all
NCT06530303
2024-11-05
BAH248
Essen Biotech
Phase 1/2
Recruiting
85 enrolled